TABLE 86Test costs: first and subsequent years

TreatmentCost (£) (pre-treatment)Cost (£) (steady-state yearly)Cost (£) (additional in first year)
MTX30.27107.2835.76
LEF12.5453.6454.12
GST12.54108.36180.60
CyA16.9352.6853.96
AZA12.45107.2853.64

From: 4, Assessment of cost-effectiveness

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.